Prostaglandin E2 inhibits advanced glycation end product-induced adhesion molecule expression, cytokine production, and lymphocyte proliferation in human peripheral blood mononuclear cells

Journal of Pharmacology and Experimental Therapeutics

Volumn 331, Issue 2, 2009, Pages 656-670

  Takahashi, Hideo Kohka ^a   Liu, Keyue ^a   Wake, Hidenori ^a   Mori, Shuji ^b   Zhang, Jiyong ^a   Liu, Rui ^a   Yoshino, Tadashi ^a   Nishibori, Masahiro ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b SHUJITSU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

11,15 O DIMETHYLPROSTAGLANDIN E2; 16 (3 METHOXYMETHYL)PHENYL OMEGA TETRANOR 3,7 DITHIA PROSTAGLANDIN E1; 6 ISOPROPOXY 9 OXO 2 XANTHENECARBOXYLIC ACID; 7 [5 (4 BIPHENYLYLMETHOXY) 2 MORPHOLINO 3 OXOCYCLOPENTYL] 4 HEPTENOIC ACID; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT 2; ADVANCED GLYCATION END PRODUCT 3; ADVANCED GLYCATION END PRODUCT RECEPTOR; B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; CELL ADHESION MOLECULE; CYCLIC AMP; FORSKOLIN; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; ONO AE1 259 01; ONO AE1 329; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E1 RECEPTOR; PROSTAGLANDIN E2; PROSTAGLANDIN E4 RECEPTOR; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; PROSTANOID RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ADENYLATE CYCLASE; BUCLADESINE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYTOKINE; ISOQUINOLINE DERIVATIVE; N (2 (4 BROMOCINNAMYLAMINO)ETHYL) 5 ISOQUINOLINESULFONAMIDE; N-(2-(4-BROMOCINNAMYLAMINO)ETHYL)-5-ISOQUINOLINESULFONAMIDE; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E RECEPTOR 4; PTGER2 PROTEIN, HUMAN; PTGER4 PROTEIN, HUMAN; SULFONAMIDE;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIABETES MELLITUS; DRUG ANTAGONISM; HUMAN; HUMAN CELL; IMMUNOMODULATION; INFLAMMATION; INTERFERON PRODUCTION; LYMPHOCYTE PROLIFERATION; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; BIOSYNTHESIS; CELL PROLIFERATION; CELL SEPARATION; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVATION; FLOW CYTOMETRY; IN VITRO STUDY; LYMPHOCYTE; METABOLISM;

ADENYLATE CYCLASE; BUCLADESINE; CELL ADHESION MOLECULES; CELL PROLIFERATION; CELL SEPARATION; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYTOKINES; DINOPROSTONE; ENZYME ACTIVATION; FLOW CYTOMETRY; FORSKOLIN; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; ISOQUINOLINES; LYMPHOCYTES; MONOCYTES; RECEPTORS, PROSTAGLANDIN E; RECEPTORS, PROSTAGLANDIN E, EP2 SUBTYPE; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; SULFONAMIDES;

EID: 70350457951     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.157594     Document Type: Article

References (41)

1. Bierhaus A, Hofmann MA, Ziegler R, and Nawroth PP (1998) AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 37:586-600. (Pubitemid 28231153)
2. Bierhaus A, Illmer T, Kasper M, Luther T, Quehenberger P, Tritschler H, Wahl P, Ziegler R, Müller M, and Nawroth PP (1997) Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. Circulation 96:2262-2271. (Pubitemid 27425832)
3. Brownlee M, Cerami A, and Vlassara H (1988) Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318:1315-1321. (Pubitemid 18126831)
4. Burke AP, Kolodgie FD, Zieske A, Fowler DR, Weber DK, Varghese PJ, Farb A, and Virmani R (2004) Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol 24:1266-1271. (Pubitemid 38880019)
5. Camacho SA, Heath WR, Carbone FR, Sarvetnick N, LeBon A, Karlsson L, Peterson PA, and Webb SR (2001) A key role for ICAM-1 in generating effector cells mediating inflammatory responses. Nat Immunol 6:523-529. (Pubitemid 33705854)
6. Coleman RA, Smith WL, and Narumiya S (1994) VIII. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptor and their subtypes. Pharmacol Rev 46:205-229.
7. Cuccurullo C, Iezzi A, Fazia ML, De Cesare D, Di Francesco A, Muraro R, Bei R, Ucchino S, Spigonardo F, Chiarelli F, et al. (2006) Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol 26:2716-2723. (Pubitemid 44777287)
8. Durie FH, Foy TM, Masters SR, Laman JD, and Noelle RJ (1994) The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol Today 9:406-411. (Pubitemid 24272184)
9. Enomoto M, Adachi H, Yamagishi S, Takeuchi M, Furuki K, Hino A, Hiratsuka A, Takajo Y, and Imaizumi T (2006) Positive association of serum levels of advanced glycation end products with thrombogenic markers in humans. Metabolism 55:912-917. (Pubitemid 43902894)
10. Fitzsimmons C, Proudfoot D, and Bowyer DE (1999) Monocyte prostaglandins inhibit procollagen secretion by human vascular smooth muscle cells: implications for plaque stability. Atherosclerosis 142:287-293. (Pubitemid 29059486)
11. Fukami K, Ueda S, Yamagishi S, Kato S, Inagaki Y, Takeuchi M, Motomiya Y, Bucala R, Iida S, Tamaki K, et al. (2004) AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int 66:2137-2147. (Pubitemid 41115277)
12. Ge J, Jia Q, Liang C, Luo Y, Huang D, Sun A, Wang K, Zou Y, and Chen H (2005) Advanced glycosylation end products might promote atherosclerosis through inducing the immune maturation of dendritic cells. Arterioscler Thromb Vasc Biol 25:2157-2163. (Pubitemid 41416315)
13. Hempel SL, Monick MM, and Hunninghake GW (1994) Lipopolysaccharide induces prostaglandin H synthase-2 protein and mRNA in human alveolar macrophages and blood monocytes. J Clin Invest 93:391-396.
14. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, et al. (1999) RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97:889-901. (Pubitemid 29375048)
15. Jain SK, Kannan K, Lim G, McVie R, and Bocchini JA Jr (2002) Hyperketonemia increases tumor necrosis factor-α secretion in cultured U937 monocytes and type 1 diabetic patients and is apparently mediated by oxidative stress and cAMP deficiency. Diabetes 51:2287-2293. (Pubitemid 34729037)
16. Kay LJ, Yeo WW, and Peachell PT (2006) Prostaglandin E2 activates EP2 receptors to inhibit human lung mast cell degranulation. Br J Pharmacol 147:707-713.
17. Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, and Schmidt AM (1997) Activation of the receptor for advanced glycation end products triggers a p21(ras)- dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 272:17810-17814. (Pubitemid 27311222)
18. Lorenowicz MJ, Fernandez-Borja M, and Hordijk PL (2007) cAMP signaling in leukocyte transendothelial migration. Arterioscler Thromb Vasc Biol 27:1014-1022. (Pubitemid 46641986)
19. Mamputu JN and Renier (2004) Advanced glycation end-products increase monocyte adhesion to retinal endothelial cells through vascular endothelial growth factor-induced ICAM-1 expression: inhibitory effect of antioxidants. J Leukocyte Biol 75:1062-1069.
20. Miyata T, Hori O, Zhang J, Yan SD, Ferran L, Iida Y, and Schmidt AM (1996) The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloidosis. J Clin Invest 98:1088-1094. (Pubitemid 26299919)
21. Nakamura K, Yamagishi SI, Matsui T, Adachi H, Takeuchi M, and Imaizumi T (2007) Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects. Clin Exp Med 7:188-190. (Pubitemid 46944961)
22. Nakamura Y, Horii Y, Nishino T, Shiiki H, Sakaguchi Y, Kagoshima T, Dohi K, Makita Z, Vlassara H, and Bucala R (1993) Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol 143:1649-1656. (Pubitemid 24058268)
23. Noguchi K, Iwasaki K, Shitashige M, Umeda M, Izumi Y, Murota S, and Ishikawa I (2001) Downregulation of lipopolysaccharide-induced intercellular adhesion molecule- 1 expression via EP2/EP4 receptors by prostaglandin E2 in human fibroblasts. Inflammation 25:75-81. (Pubitemid 32295742)
24. Okamoto T, Yamagishi S, Inagaki Y, Amano S, Koga K, Abe R, Takeuchi M, Ohno S, Yoshimura A, and Makita Z (2002) Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J 16:1928-1930.
25. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ Jr, Chow WS, Stern D, and Schmidt AM (1998) Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 4:1025-1031. (Pubitemid 28417334)
26. Penglis PS, Cleland LG, Demasi M, Caughey GE, and James MJ (2000) Differential regulation of prostaglandin E2 and thromboxane A2 production in human monocytes: implications for the use of cyclooxygenase inhibitors. J Immunol 165:1605-1611. (Pubitemid 30604598)
27. Ranger AM, Das MP, Kuchroo VK, and Glimcher LH (1996) B7-2 (CD86) is essential for the development of IL-4-producing T cells. Int Immunol 8:1549-1560. (Pubitemid 26341095)
28. Schmidt AM, Hasu M, Popov D, Zhang JH, Chen J, Yan SD, Brett J, Cao R, Kuwabara K, and Costache G (1994) Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc Natl Acad Sci U S A 91:8807-8811.
29. Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, Cao R, Yan SD, Brett J, and Stern D (1995) Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 96:1395-1403.
30. Stoll G and BendszusM(2006) Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke 37:1923-1932.
31. Suzawa T, Miyaura C, Inada M, Maruyama T, Sugimoto Y, Ushikubi F, Ichikawa A, Narumiya S, and Suda T (2000) The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology 141:1554-1559. (Pubitemid 32269125)
32. Takahashi HK, Iwagaki H, Tamura R, Xue D, Sano M, Mori S, Yoshino T, Tanaka N, and Nishibori M (2003) Unique regulation profile of prostaglandin E1 on adhesion molecule expression and cytokine production in human peripheral blood mononuclear cells. J Pharmacol Exp Ther 307:1188-1195. (Pubitemid 37494241)
33. Takahashi HK, Iwagaki H, Yoshino T, Mori S, Morichika T, Itoh H, Yokoyama M, Kubo S, Kondo E, Akagi T, et al. (2002) Prostaglandin E(2) inhibits IL-18-induced ICAM-1 and B7.2 expression through EP2/EP4 receptors in human peripheral blood mononuclear cells. J Immunol 168:4446-4454. (Pubitemid 34441346)
34. Takahashi HK, Mori S, Wake H, Liu K, Yoshino T, Ohashi K, Tanaka N, Shikata K, Makino H, and Nishibori M (2009) Advanced glycation end products subspecies-selectively induce adhesion molecule expression and cytokine production in human peripheral blood mononuclear cells. J Pharmacol Exp Ther 330:89-98.
35. Takayama K, García-Cardena G, Sukhova GK, Comander J, Gimbrone MA Jr, and Libby P (2002) Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor. J Biol Chem 277:44147-44154. (Pubitemid 36157844)
36. Takeuchi M, Makita Z, Bucala R, Suzuki T, Koike T, and Kameda Y (2000) Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol Med 6:114-125.
37. Takeuchi M and Yamagishi S (2004) TAGE (toxic AGEs) hypothesis in various chronic diseases. Medical Hypotheses 63:449-452. (Pubitemid 38993609)
38. Wake H, Takahashi HK, Mori S, Liu K, Yoshino T, and Nishibori M (2009) Histamine inhibits advanced glycation end products-induced adhesion molecule expression on human monocytes. J Pharmacol Exp Ther 330:826-833.
39. Wautier JL, Zoukourian C, Chappey O, Wautier MP, Guillausseau PJ, Cao R, Hori O, Stern D, and Schmidt AM (1996) Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest 97:238-243. (Pubitemid 26021714)
40. Yamagishi S, Amano S, Inagaki Y, Okamoto T, Koga K, Sasaki N, Yamamoto H, Takeuchi M, and Makita Z (2002) Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes. Biochem Biophys Res Commun 290:973-978. (Pubitemid 34687457)
41. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, Pinsky D, and Stern D (1994) Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 269:9889-9897. (Pubitemid 24196599)